Marie-Louise Alamaa appointed interim CFO at PledPharma

PledPharma AB (STO: PLED) today announced that Marie-Louise Alamaa takes on the position as interim CFO at PledPharma. She will join the company in July.

Marie-Louise has extensive experience within finance and controlling from public companies. Her previous positions include CFO at Index Invest International AB, various senior finance positions at Crucell Sweden AB (previously SBL Vaccin AB) and Senior Consultant at the listed gaming company Stillfront Group AB.
She has studied economics at the universities of Uppsala and Stockholm, Sweden, with a particular focus on accounting and auditing.
A process for the recruitment of a permanent CFO have been initiated.
“I am very happy to get Marie-Louise on board at PledPharma. She has a proven track-record of broad and relevant work experience in a listed environment, and with a problem-solving and team-oriented attitude, she will make an excellent addition to the team,” said Nicklas Westerholm, CEO, PledPharma.

About Us

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate Aladote® is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see http://www.pledpharma.com/